SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer is a phase 2, interventional study registered as NCT05570825 by University of Washington, with a registry enrolment figure of 30 participants, started 2023-04-06 and due to reach its primary completion in 2027-07-01. Interventions recorded: Biopsy; Biospecimen Collection; Computed Tomography; CXCR1/2 Inhibitor SX-682; Magnetic Resonance Imaging; Pembrolizumab; Positron Emission Tomography. Conditions listed: Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8. Primary outcome: Best objective response rate. Lung eligibility wording from the registry: "* Pathologically or cytologically confirmed non-small cell lung cancer with no known oncogenic EGFR mutation, ALK rearrangement, ROS1 rearrangement or RET rearrangement". Sites: United States. No results are recorded here; the registry entry is the source.